0001209191-19-054164.txt : 20191025 0001209191-19-054164.hdr.sgml : 20191025 20191025171255 ACCESSION NUMBER: 0001209191-19-054164 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190920 FILED AS OF DATE: 20191025 DATE AS OF CHANGE: 20191025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 191170689 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-20 0 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2019-09-20 4 P 0 60 5.33 A 15578 D Common Stock 2019-09-23 4 P 0 60 5.35 A 15638 D Common Stock 2019-09-24 4 P 0 60 5.39 A 15698 D Common Stock 2019-09-25 4 P 0 60 5.38 A 15758 D Common Stock 2019-09-26 4 P 0 60 5.76 A 15818 D Common Stock 2019-09-27 4 P 0 60 5.76 A 15878 D Common Stock 2019-09-30 4 P 0 60 5.89 A 15938 D Common Stock 2019-10-01 4 P 0 60 5.89 A 15998 D Common Stock 2019-10-02 4 P 0 60 5.77 A 16058 D Common Stock 2019-10-04 4 P 0 60 5.76 A 16118 D Common Stock 2019-10-07 4 P 0 60 5.74 A 16178 D Common Stock 2019-10-08 4 P 0 60 5.81 A 16238 D Common Stock 2019-10-09 4 P 0 60 5.78 A 16298 D Common Stock 2019-10-10 4 P 0 60 5.86 A 16358 D Common Stock 2019-10-11 4 P 0 60 5.71 A 16418 D Common Stock 2019-10-14 4 P 0 60 5.67 A 16478 D Common Stock 2019-10-15 4 P 0 60 5.63 A 16538 D Common Stock 2019-10-16 4 P 0 60 5.56 A 16598 D Common Stock 2019-10-17 4 P 0 60 5.52 A 16658 D Common Stock 2019-10-18 4 P 0 34 5.45 A 16692 D The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact 2019-10-25